|Day Low/High||4.01 / 4.30|
|52 Wk Low/High||1.53 / 2.72|
Clinical Study Initiation Is Expected Shortly, with Funding by NIH
NIH Grant Will Support Clinical Testing of PTI-125, an Experimental Drug Candidate
PTI-125, an Experimental Drug, Restored Receptor Function and Significantly Improved Working Memory and Spatial Ability in a Transgenic Mouse Model of Alzheimer's Disease
Stock to Trade on a Split-adjusted Basis Beginning May 10, 2017
- Company Will Host Conference Call on Tuesday, March 21st, at 8am Eastern Time -
Here's a technical look at how to trade some of the most active stocks on the market right now.
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.
These low-dollar biotech stocks are making big moves Monday -- in opposite directions.
Company Will Host Conference Call Monday, September 26th at 9:00am EDT
No Change to September 25th PDUFA Date
REMOXY NDA Has Priority Review
Focus in 2016 Will be on REMOXY, Fiscal Discipline and Advancing Pipeline
Focus Remains on NDA Resubmission to FDA, Targeted for Q1 2016
The most recent short interest data has been released by the NASDAQ for the 05/29/2015 settlement date, which shows a 650,044 share increase in total short interest for Pain Therapeutics Inc , to 3,037,711, an increase of 27.23% since 05/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Conference Call Tomorrow, Tuesday, at 4:30 p.m. Eastern Time
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.